DNA encoding procine interleukin-10

• US 5,624,823 A
• Filed: 08/30/1993
• Issued: 04/29/1997
• Est. Priority Date: 11/22/1991
• Status: Expired due to Term

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Leguern, Christian A., Blancho, Gilles JF., Sykes, Megan, Sachs, David H.
• Primary Examiner(s): Walsh, Stephen G.
• Assistant Examiner(s): KEMMERER, ELIZABETH
• Application Number:
  US08/114,072
• Time in Patent Office: 1,338 Days
• Field of Search: 536/23.5, 435/320.1, 435/69.1, 435/252.3, 435/69.52, 435/240.2
• US Class Current: 435/69.52
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2121/00 Preparations for use in therapy
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/26 Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 39/001 Preparations to induce tolerance to non-self, e.g. prior to transplantation
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 51/1282 Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
• CPC Class Codes: C07K 14/70539 MHC-molecules, e.g. HLA-molecules
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants

Abstract

Purified DNA encoding porcine IL-10, porcine IL-10, and methods of inducing immunological tolerance and inhibiting graft versus host disease.

Claims

1. Purified DNA comprising a sequence which encodes a peptide having at least 90% sequence similarity with the peptide from SEQ ID NO:

1 and said peptide having a porcine IL-10 activity, said activity being chosen from the group of;

inhibiting the ability of T cells to release or produce IL-2 when administered to T cells;

inhibiting the ability of T cells to release or produce gamma interferon when administered to T cells; and

competitively inhibiting the binding of IL-10 to cells.

2. The purified DNA of claim 1, wherein said encoded peptide has at least 95% sequence similarity with the peptide of SEQ ID NO:

1.

3. The purified DNA of claim 1, wherein said encoded peptide has at least 98% sequence similarity with the peptide of SEQ ID NO:

1.

4. The purified DNA of claim 1, wherein said DNA encodes the peptide sequence of SEQ ID NO:

1.

12. A vector comprising the purified DNA sequence of claim 1.

13. A host cell containing the purified DNA of claim 1.

14. The cell of claim 13, wherein said host cell is capable of expressing a peptide having porcine IL-10 activity.

15. An essentially homogenous population of host cells, each of which comprises the purified DNA of claim 1 or 5.

16. A method for manufacture of peptide having porcine IL-10 activity comprising culturing the host cell of claim 13 in a medium to express said peptide.

17. The purified DNA of claim 1, wherein said encoded peptide has at least 99% sequence similarity with the peptide of SEQ NO:

1.

22. The purified DNA of claim 1, wherein said peptide has the activity of inhibiting the ability of T cells to release or produce IL-2 when administered to T cells.

23. The purified DNA of claim 1, wherein said peptide has the activity of inhibiting the ability of T cells to release or produce gamma interferon when administered to T cells.

24. The purified DNA of claim 1, wherein said peptide has the activity of competitively inhibiting the binding of IL-10 to cells.

25. The purified DNA of claim 24, wherein said peptide has the activity of competitively inhibiting the binding of porcine IL-10 to porcine T cells.

5. Purified DNA comprising a sequence encoding a peptide of 30 or more amino acids in length said peptide being a fragment of SEQ ID NO:

1.

6. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 40 amino acids in length.

7. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 50 amino acids in length.

8. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 60 amino acids in length.

9. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 80 amino acids in length.

10. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 100 amino acids in length.

11. The purified DNA sequence of claim 5, wherein said DNA encodes a peptide which is at least 120 amino acids in length.

18. A vector comprising the purified DNA sequence of claim 5.

19. A host cell containing the purified DNA of claim 5.

20. The host cell of claim 19, wherein said cell is capable of expressing a peptide which is a fragment at least 30 amino acids long of the peptide of SEQ ID NO:

1.

21. A method for manufacture of a peptide which is a fragment at least 30 amino acids long of the peptide of SEQ ID NO:

1 comprising culturing the host cell of claim 20 in a medium to express said peptide.

26. Purified DNA comprising a sequence which encodes the peptide of SEQ ID NO:

1.

27. Purified DNA which comprises the nucleic acid sequence of SEQ ID NO:

1.